The Remarkable Selectivity of Nirmatrelvir.
ACS Pharmacol Transl Sci
; 5(6): 445-447, 2022 Jun 10.
Article
in English
| MEDLINE | ID: covidwho-1908097
ABSTRACT
The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 Mpro but also minimal polypharmacology versus human cysteine proteases. This Viewpoint explores the activity profile of the first approved SARS-CoV-2 Mpro inhibitor (Nirmatrelvir) versus a panel of cysteine proteases and considers the therapeutic implications of the data.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
ACS Pharmacol Transl Sci
Year:
2022
Document Type:
Article
Affiliation country:
Acsptsci.2c00065
Similar
MEDLINE
...
LILACS
LIS